A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.
Non Small Cell Lung Cancer
DRUG: Entinostat|DRUG: Erlotinib
Disease Control Rate (Complete Response, Partial Response, or Stable Disease for at Least 3 Months, At least 3 months
Progression-free Survival Rate, Up to 4 months
To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.